3′-substituted methyl or alkynyl nucleosides nucleotides for the treatment of HCV
US10202411B2 · kind B2 · utility
1Cited by
168References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 16, 2015 |
| Grant date | Feb 12, 2019 |
| Priority date | — |
| Expiry date | May 29, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/708
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.